retatrutide weight loss efficacy New Phase 3 data just dropped 👀 Eli Lilly's trial reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Phase III retatrutide study demonstrates

People with diabetes may need special attention in any incretin-related study because changes in appetite, weight, and glucose can interact with existing medicines

Resistance training addresses both concerns simultaneously by applying mechanical load to both muscles and bones

Comprehensive Weight Loss Solutions In addition to GLP-1 medications, Liquid Mobile provides an array of fast and affordable weight management options, including: Peptides: Target specific health goals, from weight loss to muscle growth

Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023

The SELECT trial results established GLP-1 receptor activation as cardioprotective in ways that previous surrogate marker improvements only suggested

Every meal needs to deliver maximum nutritional value because you are eating fewer of them